John O Mascarenhas
Hematology & Oncology · Icahn School of Medicine at Mount Sinai
Credentials: · ·
History
Research
Complement-dependent clearance of apoptotic cells by human macrophages
The Journal of Experimental Medicine · 1998 · 527 citations
JAMA Oncology · 2018 · First of 19 authors · 347 citations
MDM2 inhibition: an important step forward in cancer therapy
Review · Leukemia · 2020 · 319 citations
97 papers
84 papers
56 papers
50 papers
- RR
47 papers · 4 as a fellow
29 papers
- SV
29 papers
25 papers
Grants
- 2006–2028
Myeloproliferative Neoplasms-Research Consortium
National Cancer Institute · P01
Project lead · $6.4M · Icahn School of Medicine at Mount Sinai
- 2020–2021
Prevalence of Chronic Hematopoiesis of Indeterminate Potential Among WTC Responders
NIOSH · U01
Contact PI · $999.3K · Icahn School of Medicine at Mount Sinai
Clinical trials
- 2024–2028
Principal investigator · Recruiting · Phase 1
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- 2013–2017
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Principal investigator · Terminated · Phase 2
John Mascarenhas
- 2013–2018
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Principal investigator · Completed · Phase 1, Phase 2
John Mascarenhas
- 2011–2016
Principal investigator · Completed · Phase 2
Ronald Hoffman